TG Therapeutics gets rights to Hengrui's Btk inhibitor program

Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276) granted TG Therapeutics Inc. (NASDAQ:TGTX) worldwide rights, excluding Asia but including Japan, to its Bruton's tyrosine kinase (Btk) inhibitor program.

Hengrui will receive up to $350 million including an undisclosed up-front payment and milestones. The company is also eligible for tiered royalties...